The efficacy and safety of transdermal XXXX for the prevention of @entity1209 : a quantitative systematic review.

@entity1 @entity227 @entity390 @entity2133 @entity391 @entity5591 @entity1209
The role of @entity5591 administered via transdermal therapeutic systems in the prevention of @entity1209 , @entity390 , and @entity390 and @entity391 is unclear. We performed a systematic search for full reports of randomized comparisons of transdermal @entity5591 with inactive control. Dichotomous data were extracted. In the meta-analysis, relative risks and numbers-needed-to-treat/harm were calculated with 95% confidence intervals (CI). In 23 trials, 979 @entity1 received transdermal @entity5591 , and 984 @entity1 received placebo. Sensitivity analyses were performed using restricted data for truncated control event rates (40%-80%) and for large trials. With these data, the relative @entity1209 (five reports), @entity390 (five reports), @entity390 and @entity391 (eight reports), and rescue treatment (three reports) were 0.69 (95% CI, 0.58-0.82), 0.69 (95% CI, 0.54-0.87), 0.76 (95% CI, 0.66-0.88), and 0.68 (95% CI, 0.54-0.85), respectively. This means that of 100 @entity1 who receive transdermal @entity5591 , approximately 17 will not experience @entity1209 who would have done so had they all received a placebo. However, 18 of 100 @entity1 will have @entity227 , eight will report @entity2133 , two will report dizziness, one will be classified as being agitated, and 1-13 @entity1 who are prescribed transdermal @entity5591 will not use it correctly. The timing of application does not alter efficacy. IMPLICATIONS: Of 100 @entity1 who receive transdermal @entity5591 , approximately 17 will not vomit in the postoperative period who would have done so had they all received a placebo. However, 18 of 100 @entity1 will have @entity227 , and eight will report @entity2133 . Incorrect use further limits its efficacy.
